Added value of spectral parameters in diagnosing metastatic lymph nodes of pT1-2 rectal cancer

Liu, Jinkai; Pan, Hao; Lin, Qi; Chen, Xingbiao; Huang, Zhenhuan; Huang, Xiong-hua; Tang, Langlang

doi:10.1007/s00261-023-03854-9

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven thousand one hundred and sixty‐five (53.4%) and underwent resection within 5–8 weeks from completion of neoadjuvant therapy compared to 6261 (46.6%) within 9–12 weeks. These rates are similar to previous large‐volume studies in a similar population 15 . The most common surgical procedure was LAR ( n = 8468, 63.1%) followed by APR ( n = 3501, 26.1%).…”

Section: Resultssupporting

confidence: 88%

See 1 more Smart Citation

Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut‐offs by disease response

Wehrle,

Woo,

Chang

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

IntroductionA minimum lymph node harvest (LNH) of 12 is the current standard for appropriate nodal staging in resectable rectal cancer. However, the rise of neoadjuvant chemoradiation (NCRT) and total neoadjuvant therapy (TNT) has been associated with decreasing number of LNH. We hypothesize that as tumor response to neoadjuvant therapy increases, the optimum for LNH to achieve appropriate nodal staging should decrease.MethodsPatients with clinical stage III rectal adenocarcinoma who underwent NCRT/TNT followed by resection were identified from the National Cancer Database. A JoinPoint regression analysis was used to determine the LNH for each tumor regression grade (TRG) category beyond which the rate of positive nodes does not significantly change.ResultsThirteen thousand four hundred and twenty‐six patients met inclusion criteria. Of these, 2406 (17.9%) achieved TRG 0 or ypT0 and 8210 (61.2%) achieved ypN0. Collectively, 2043 patients (15.2%) were reported to have a pathologic complete response (ypT0 ypN0). Positive pathologic nodes were found in 15%, 23%, 31%, 54%, and 53% as ypT stage increased from ypT0 to ypT4, respectively. Similarly, ypN+ rates were 15%, 36%, 41%, and 55% in TRG 0–3. No JoinPoint was identified for TRG 0, whereas inflection points were found at 6–10 nodes for TRG1 (p = 0.002) and TRG 2 (p = 0.016), and at 11–15 nodes for TRG 3.ConclusionThe benchmark of retrieving 12 nodes in resectable stage III rectal cancer is not consistently achieved after NCRT/TNT. We demonstrate that the LNH requirement to establish accurate pathologic nodal staging can vary depending on the tumor response to neoadjuvant therapies.

show abstract

Section: Resultssupporting

confidence: 88%

“…These rates are similar to previous large-volume studies in a similar population. 15 The most common surgical procedure was LAR (n = 8468, 63.1%) followed by APR (n = 3501, 26.1%). Table 1 is a summary of the demographic and clinical characteristics of the selected patient population.…”

Section: Resultsmentioning

confidence: 98%

Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut‐offs by disease response

Wehrle,

Woo,

Chang

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

The clinical applications of dual-layer spectral detector CT in digestive system diseases

Chen,

Liu,

Zeng

et al. 2024

Eur Radiol

View full text Add to dashboard Cite

Objective Dual-layer spectral detector CT (DLCT) has several advantages in clinical practice, this study aims to reveal the clinical applications of DLCT in digestive system diseases. Materials and methods We searched PubMed and Cochrane Reviews for articles published from January 1, 2010 to May 31, 2024, using the terms “dual-layer spectral detector CT” or “dual-layer CT” combined with “hepatic fat” or “hepatic fibrosis” “hepatocellular carcinoma” or “pancreatic ductal adenocarcinoma” or “pancreatic neuroendocrine tumors” or "gastric cancer" or "colorectal cancer" or "Crohn’s disease" or "bowel ischemia" or "acute abdominal conditions". Results DLCT consists of a top layer sensitive to lower-energy photons and a bottom layer sensitive to higher-energy photons. This configuration enables simultaneous acquisition of two energy spectra from a single X-ray beam ensuring consistent spatial alignment and temporal resolution. Spectral raw images allow image post-processing to improve image quality, reduce radiation doses and contrast media doses, and generate multiple quantitative parameters. It has broad potential for early detection, accurate staging, efficacy assessment, and prognosis prediction of liver, pancreatic, and gastrointestinal diseases, as well as for the assessment of digestive system vasculature. Conclusions DLCT not only provides valuable information for the clinical diagnosis and therapeutic effect evaluation of digestive system diseases but also may play a more important role in the overall management of digestive diseases and in the decision-making of individualized medicine. Key Points QuestionWhat are the advantages of DLCT compared to traditional single-energy CT in the early detection, staging, and therapeutic evaluation of digestive system diseases? FindingsDLCT enhances image quality, improves tissue characterization, and allows for multi-parametric analysis, making it superior in detecting and evaluating liver, pancreatic, and gastrointestinal diseases. Clinical relevanceDLCT provides high-quality, multi-parametric imaging that improves the accuracy of diagnosing digestive diseases, facilitates more precise treatment planning, and enhances monitoring of treatment response, ultimately contributing to better patient management and prognosis.

show abstract

Spectral CT in the evaluation of perineural invasion status in rectal cancer

Lu,

Tan,

Zhong

et al. 2024

Jpn J Radiol

View full text Add to dashboard Cite

Added value of spectral parameters in diagnosing metastatic lymph nodes of pT1-2 rectal cancer

Cited by 4 publications

References 25 publications

Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut‐offs by disease response

Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut‐offs by disease response

The clinical applications of dual-layer spectral detector CT in digestive system diseases

Spectral CT in the evaluation of perineural invasion status in rectal cancer

Contact Info

Product

Resources

About